GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

Conditions:   Gastric Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma
Interventions:   Drug: GS-5745;   Drug: Nivolumab
Sponsor:   Gilead Sciences
Not yet recruiting - verified August 2016

from #ENT via xlomafota13 on Inoreader http://ift.tt/2aOzZx7
via IFTTT